01

RP1–nivolumab preserves quality-adjusted survival in melanoma

Phase 1/2 IGNYTE data show RP1 plus nivolumab produced 2.81 QALYs and 32.2 months’ median overall survival in 121 patients with advanced melanoma after anti–PD-1 therapy.